ReviewHuman vaccines & immunotherapeutics2026
Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36.Journal of virology · 2026Trial
- The State-of-the Art of Personalized Vaccines for Non-Communicable Diseases: A Narrative Review.Vaccines · 2026Review
- Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a comprehensive analysis of the molecular innovations driving vaccine adjuvant research, moving from empirical formulations to rational designs. After outlining clinical benchmarks, we systematically categorize and evaluate emerging experimental adjuvant classes, including cytokine-based agonists, advanced particulate delivery systems, emulsion-based platforms, and nucleotide-based strategies. Notably, we focus on natural product-derived adjuvants, highlighting how their structure-activity relationships (SAR) drive potent immunomodulatory activities. We further dissect the molecular mechanisms underpinning these adjuvants, detailing how they target specific pattern recognition receptors (PRRs) to orchestrate dendritic cell maturation, antigen cross-presentation, and Th1/Th2 polarization. Crucially, we discuss the rational selection of adjuvants based on specific clinical targets and antigen modalities. Finally, we propose a forward-looking perspective on developing multi-modal strategies that synergize molecular immunostimulants with synthetic delivery vectors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.